Selected article for: "PCR base and testing capacity"
Author: Devon Chandler-Brown; Anna M. Bueno; Oguzhan Atay; David S. Tsao
Title: A Highly Scalable and Rapidly Deployable RNA Extraction-Free COVID-19 Assay by Quantitative Sanger Sequencing
  • Document date: 2020_4_10
    • ID: eui41zyg_20
    Snippet: In addition not requiring RNA extraction kits, our qSanger-based COVID-19 assay has a number of additional advantages compared to existing qPCR-based tests for COVID-19. Importantly, qSanger thermal cycling occurs in higher-throughput end-point PCR instruments, rather than specialized qPCR instruments, and the sequencing can be run in automated Sanger sequencers with plate feeders such as Applied Biosystems 3730xl DNA Analyzers which have the cap.....
    Document: In addition not requiring RNA extraction kits, our qSanger-based COVID-19 assay has a number of additional advantages compared to existing qPCR-based tests for COVID-19. Importantly, qSanger thermal cycling occurs in higher-throughput end-point PCR instruments, rather than specialized qPCR instruments, and the sequencing can be run in automated Sanger sequencers with plate feeders such as Applied Biosystems 3730xl DNA Analyzers which have the capacity to sequence 3840 samples per day. The large existing install-base of end-point PCR and high-throughput Sanger instruments throughout the US and the world [14] supports rapid scale-up of qSanger-COVID-19 assays without requiring any new device or instrument manufacturing. Given that Sanger sequencing is still the most widely used method of clinical sequencing worldwide, the widespread adoption of qSanger-COVID-19 assay described here can create >1M COVID-19 testing capacity per day.

    Search related documents:
    Co phrase search for related documents
    • clinical sequencing and day testing capacity: 1
    • clinical sequencing and extraction kit: 1
    • clinical sequencing and high throughput: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • day testing capacity and high throughput: 1
    • describe qSanger assay and end point: 1
    • end point and high throughput: 1, 2, 3, 4, 5, 6
    • end point and new device: 1, 2
    • extraction kit and high throughput: 1, 2
    • extraction kit and PCR instrument: 1, 2, 3, 4, 5, 6
    • high throughput and new device: 1
    • high throughput and PCR instrument: 1, 2, 3
    • high throughput and qpcr base: 1
    • instrument new device and new device: 1